Compounds > 5-iodobenzovesamicol
Page last updated: 2024-12-07

5-iodobenzovesamicol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-iodobenzovesamicol: radiotracer for mapping cholinergic neurons of the brain; structure given in first source; RN given is for (2R-trans) isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124499
CHEMBL ID65239
SCHEMBL ID21104710
MeSH IDM0179009

Synonyms (20)

Synonym
CHEMBL65239 ,
(2r,3r)-5-iodo-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol
5-iodobenzovesamicol
(2r,3r)-5-iodo-3-(4-phenyl-piperidin-1-yl)-1,2,3,4-tetrahydro-naphthalen-2-ol
bdbm50329775
(rac)-5-iodo-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol
5-iodo-3-(4-phenyl-piperidin-1-yl)-1,2,3,4-tetrahydro-naphthalen-2-ol([i125]-(-)ibvm)
5-ibvm
2-naphthalenol, 1,2,3,4-tetrahydro-5-iodo-3-(4-phenyl-1-piperidinyl)-, (2r-trans)-
128192-12-1
ihv0x7kk9b ,
unii-ihv0x7kk9b
DTXSID90155836
SCHEMBL21104710
2-naphthalenol, 1,2,3,4-tetrahydro-5-iodo-3-(4-phenyl-1-piperidinyl)-, (2r,3r)-
(-)-ibvm
5-iodobenzovesamicol, l-
(-)-5-iodobenzovesamical
ibvm
5-iodobenzovesamical, (-)-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vesicular acetylcholine transporterRattus norvegicus (Norway rat)Ki0.01580.00130.56224.5230AID526874
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Ki0.26600.00030.26715.0700AID526875
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID18377Tissue distribution of [125I]- labelled compound in mice lung in 24 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18365Tissue distribution of [125I]- labelled compound in mice cortex in 4 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18382Tissue distribution of [125I]- labelled compound in mice ventricle in 24 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18372Tissue distribution of [125I]- labelled compound in mice latria in 0.5 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18356Tissue distribution of [125I]- labelled compound in mice blood in 0.5 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18553Tissue distribution of [125I]- labelled compound in mice ventricles in 4 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID526875Displacement of (-)-[3H]pentazocine from sigma 1 receptor in rat cortical membranes after 120 mins2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
3D QSAR study, synthesis, and in vitro evaluation of (+)-5-FBVM as potential PET radioligand for the vesicular acetylcholine transporter (VAChT).
AID18370Tissue distribution of [125I]- labelled compound in mice hyphal in 24 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18367Tissue distribution of [125I]- labelled compound in mice hippocampus in 24 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18354Tissue distribution of [125I]- labelled compound in mice atria in 24 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID526876Displacement of (-)-[3H]DTG from sigma 2 receptor in rat liver membranes after 120 mins2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
3D QSAR study, synthesis, and in vitro evaluation of (+)-5-FBVM as potential PET radioligand for the vesicular acetylcholine transporter (VAChT).
AID18381Tissue distribution of [125I]- labelled compound in mice striatum in 4 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID139828Evaluated for the radiotracer concentration in cerebellum of mouse brain, 4 hr after intravenous injection1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
A radiotracer for mapping cholinergic neurons of the brain.
AID18380Tissue distribution of [125I]- labelled compound in mice striatum in 24 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18368Tissue distribution of [125I]- labelled compound in mice hippocampus in 4 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID526874Displacement of (-)-[3H]vesamicol from rat VAChT expressed in rat PC12 cells after 60 mins2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
3D QSAR study, synthesis, and in vitro evaluation of (+)-5-FBVM as potential PET radioligand for the vesicular acetylcholine transporter (VAChT).
AID18366Tissue distribution of [125I]- labelled compound in mice hippocampus in 0.5 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID139830Evaluated for the radiotracer concentration in striatum of mouse brain, 4 hr after intravenous injection1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
A radiotracer for mapping cholinergic neurons of the brain.
AID139829Evaluated for the radiotracer concentration in cerebral cortex of mouse brain, 4 hr after intravenous injection1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
A radiotracer for mapping cholinergic neurons of the brain.
AID18371Tissue distribution of [125I]- labelled compound in mice hyphal in 4 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18369Tissue distribution of [125I]- labelled compound in mice hyphal in 0.5 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18355Tissue distribution of [125I]- labelled compound in mice atria in 4 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID526877Selectivity ratio of Ki for sigma 1 receptor in rat cortical membranes to Ki for rat VAChT2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
3D QSAR study, synthesis, and in vitro evaluation of (+)-5-FBVM as potential PET radioligand for the vesicular acetylcholine transporter (VAChT).
AID18360Tissue distribution of [125I]- labelled compound in mice cerebellum in 0.5 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18361Tissue distribution of [125I]- labelled compound in mice cerebellum in 24 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18363Tissue distribution of [125I]- labelled compound in mice cortex in 0.5 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18373Tissue distribution of [125I]- labelled compound in mice liver in 0.5 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18375Tissue distribution of [125I]- labelled compound in mice liver in 4 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18364Tissue distribution of [125I]- labelled compound in mice cortex in 24 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18357Tissue distribution of [125I]- labelled compound in mice blood in 24 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18378Tissue distribution of [125I]- labelled compound in mice lung in 4 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18376Tissue distribution of [125I]- labelled compound in mice lung in 0.5 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18552Tissue distribution of [125I]- labelled compound in mice ventricles in 0.5 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18359Tissue distribution of [125I]- labelled compound in mice blood in 4 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18379Tissue distribution of [125I]- labelled compound in mice striatum in 0.5 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID18374Tissue distribution of [125I]- labelled compound in mice liver in 24 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
AID139827Percentage dose injected in the whole brain of mouse was determined.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
A radiotracer for mapping cholinergic neurons of the brain.
AID18362Tissue distribution of [125I]- labelled compound in mice cerebellum in 4 hours1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (29.41)18.2507
2000's8 (47.06)29.6817
2010's4 (23.53)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.40 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (11.76%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (88.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
choline
[no description available]		1.9710cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
vesamicol
vesamicol: RN given refers to parent cpd; structure		2.3820piperidines
tetrabenazine
9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one : A benzoquinolizine that is 1,2,3,4,4a,9,10,10a-octahydrophenanthrene in which the carbon at position 10a is replaced by a nitrogen and which is substituted by an isobutyl group at position 2, an oxo group at position 3, and methoxy groups at positions 6 and 7.		4.3622benzoquinolizine;
cyclic ketone;
tertiary amino compound
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		2.8940benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
peracetic acid
Peracetic Acid: A liquid that functions as a strong oxidizing agent. It has an acrid odor and is used as a disinfectant.. peracetic acid : A peroxy acid that is acetic acid in which the OH group is substituted by a hydroperoxy group. It is a versatile oxidising agent that is used as a disinfectant.		1.9810a peroxy aciddisinfectant;
oxidising agent
2-naphthylamine
2-Naphthylamine: A naphthalene derivative with carcinogenic action.. 2-naphthylamine : A naphthylamine carrying the amino group at position 2.		1.9810naphthylaminecarcinogenic agent
dihydrotetrabenazine
dihydrotetrabenazine: RN given refers to cpd without isomeric designation		4.3622isoquinolines
chloramine-t
chloramine-T: RN given refers to unlabeled parent cpd. chloramine T : An organic sodium salt derivative of toluene-4-sulfonamide with a chloro substituent in place of an amino hydrogen.		1.9810organic sodium saltallergen;
antifouling biocide;
disinfectant
a 85380
A 85380: structure given in first source; A-85380 is the S-enantiomer; A-159470 is the R-enantiomer		2.0310
benzovesamicol
benzovesamicol: structure in first source		2.0310
cellulose
DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.		1.9810glycoside
piperidines
Piperidines: A family of hexahydropyridines.		6.1162
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Confusional Senile Dementia
[description not available]		02.3920
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.3920
Cortical Lewy Body Disease
[description not available]		02.1510
Lewy Body Disease
A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)		02.1510
Autism-Dementia-Ataxia-Loss of Purposeful Hand Use Syndrome
[description not available]		02.0710
Rett Syndrome
An inherited neurological developmental disorder that is associated with X-LINKED INHERITANCE and may be lethal in utero to hemizygous males. The affected female is normal until the age of 6-25 months when progressive loss of voluntary control of hand movements and communication skills; ATAXIA; SEIZURES; autistic behavior; intermittent HYPERVENTILATION; and HYPERAMMONEMIA appear. (From Menkes, Textbook of Child Neurology, 5th ed, p199)		02.0710
Ophthalmoplegia, Progressive Supranuclear
[description not available]		02.0710
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0710
Supranuclear Palsy, Progressive
A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)		02.0710
Cervical Dystonia
A common form of DYSTONIA due to involuntary sustained or spasmodic, repetitive muscle contractions in the neck region. According to the position of the twisted neck and head, cervical dystonia can be categorized as torticollis, laterocollis, retrocollis, and a combination of these abnormal postures.		02.0110
Torticollis
A symptom, not a disease, of a twisted neck. In most instances, the head is tipped toward one side and the chin rotated toward the other. The involuntary muscle contractions in the neck region of patients with torticollis can be due to congenital defects, trauma, inflammation, tumors, and neurological or other factors.		02.0110
Multiple System Atrophy Syndrome
[description not available]		04.3622
Behavior Disorder, Rapid Eye Movement Sleep
[description not available]		03.411
Multiple System Atrophy
A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)		04.3622
REM Sleep Behavior Disorder
A disorder characterized by episodes of vigorous and often violent motor activity during REM sleep (SLEEP, REM). The affected individual may inflict self injury or harm others, and is difficult to awaken from this condition. Episodes are usually followed by a vivid recollection of a dream that is consistent with the aggressive behavior. This condition primarily affects adult males. (From Adams et al., Principles of Neurology, 6th ed, p393)		03.411
Apnea, Obstructive Sleep
[description not available]		03.411
Sleep Apnea, Obstructive
A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)		03.411
Amentia
[description not available]		02.0410
Dementia
An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.		02.0410